Pharsight

Abilify patents expiration

ABILIFY's oppositions filed in EPO
ABILIFY Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9359302 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(11 months ago)

US8580796 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(11 months ago)

US8642760 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Sep, 2022

(11 months ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7053092 OTSUKA 5-HT1a receptor subtype agonist
Jan, 2022

(1 year, 7 months ago)

US8642600 OTSUKA Method of treating autism
Jan, 2022

(1 year, 7 months ago)

US9089567 OTSUKA Method of treating cognitive impairments and schizophrenias
Jan, 2022

(1 year, 7 months ago)

US6977257 OTSUKA Aripiprazole oral solution
Apr, 2022

(1 year, 5 months ago)

US8642600

(Pediatric)

OTSUKA Method of treating autism
Jul, 2022

(1 year, 1 month ago)

US6977257

(Pediatric)

OTSUKA Aripiprazole oral solution
Oct, 2022

(10 months ago)

US8580796

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Mar, 2023

(6 months ago)

US8642760

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Mar, 2023

(6 months ago)

US9387182 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Dec, 2023

(2 months from now)

US8017615 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2024

(8 months from now)

US7115587 OTSUKA Aripiprazole complex formulation and method
Jul, 2024

(9 months from now)

US7550445 OTSUKA Aripiprazole complex formulation and method
Jul, 2024

(9 months from now)

US8017615

(Pediatric)

OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Dec, 2024

(1 year, 2 months from now)

US7550445

(Pediatric)

OTSUKA Aripiprazole complex formulation and method
Jan, 2025

(1 year, 3 months from now)

US7115587

(Pediatric)

OTSUKA Aripiprazole complex formulation and method
Jan, 2025

(1 year, 3 months from now)

US9125939 OTSUKA Carbostyril derivatives and mood stabilizers for treating mood disorders
Jul, 2026

(2 years from now)

US8759350 OTSUKA Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
Mar, 2027

(3 years from now)

Abilify is owned by Otsuka.

Abilify contains Aripiprazole.

Abilify has a total of 20 drug patents out of which 11 drug patents have expired.

Expired drug patents of Abilify are:

  • US7053092
  • US8642600
  • US9089567
  • US6977257
  • US8642600*PED
  • US6977257*PED
  • US8580796*PED
  • US8642760*PED
  • US9359302
  • US8580796
  • US8642760

Abilify was authorised for market use on 15 November, 2002.

Abilify is available in tablet;oral dosage forms.

Abilify can be used as treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar i disorder, adjunctive treatment of major depressive disorder, and treatment of irritability associated with autistic disorder, treatment of major depressive disorder (mdd), adjunctive treatment of major depressive disorder (mdd), treatment of schizophrenia, treatment of irritability associated with autistic disorder, acute treatment of manic and mixed episodes associated with bipolar i disorder.

The generics of Abilify are possible to be released after 02 March, 2027.

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 15 November, 2002

Treatment: Treatment of major depressive disorder (mdd); Treatment of irritability associated with autistic disorder; Treatment of schizophrenia; Adjunctive treatment of major depressive disorder (mdd); Acute tr...

Dosage: TABLET;ORAL

How can I launch a generic of ABILIFY before it's drug patent expiration?
More Information on Dosage

ABILIFY family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic